新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 生物制药 » 百时美与Five Prime达成$3.5亿免疫肿瘤学合作

百时美与Five Prime达成$3.5亿免疫肿瘤学合作

来源:生物谷 2014-03-18 08:33

2014年3月17日讯 /生物谷BIOON/ --百时美施贵宝(BMS)和Five Prime制药3月17日联合宣布,双方已达成一笔3.5亿美元的合作协议,发现、开发和商业化靶向2个未公开的免疫检查点信号通路(immune checkpoint pathways)的免疫-肿瘤学疗法。免疫肿瘤学,主要专注于开发非常有前途的方法来发动强大的机体免疫系统攻击癌症。

根据协议条款,百时美已同意支付2000万美元预付款、950万美元研究资金、2100万美元购买Five Prime 4.9%的流通股,同时已承诺高达3亿美元的相关里程碑款项及特许权使用费。

百时美施贵宝将利用Five Prime公司专有的靶标发现平台,通过鉴定最可行的药物靶标用于研究和临床开发,来推进自身已有的免疫-肿瘤学项目。针对这些新靶标和已有靶标而开发出来的候选药物,可能会作为一种单药或与现有或百时美施贵宝管线中有前途的免疫肿瘤学疗法进行联合用药研究。百时美施贵宝将拥有所合作产品的全球独家开发和商业化权利。

关于Five Prime制药

Five Prime是一家临床阶段的生物技术公司,致力于发现和开发新颖的蛋白疗法,用于癌症和炎症性疾病的治疗。Five Prime已利用其全面的人类胞外蛋白文库和专有的高通量筛选技术,发现蛋白质疗法的新靶标,并由合作伙伴推进,或发掘其自身管线中蛋白质疗法的新靶标。

目前,Five Prime有2个蛋白疗法(FP-1039和FPA008)处于临床试验,第3个疗法(PA144)预计将于2014年进入临床试验。此外,该公司正与葛兰素史克(GSK)合作开发FP-1039(GSK3052230)用于多种实体瘤的治疗,这是一种成纤维细胞生长因子(FGF)配体陷阱(ligand trap)。

一项全球性、多组Ib期研究,正在调查FP-1039与标准化疗用于FGFR1基因扩增的鳞状非小细胞肺癌(NSLCL)和间皮瘤的治疗。FPA008是一种单克隆抗体,能够抑制集落刺激因子1受体(CSF1R)的激活,目前正处于I期临床,开发用于类风湿性关节炎的治疗。PA144是一种单克隆抗体,能够阻断通过成纤维细胞生长因子受体2b(FGFR2b)的信号,目前已糖基工程化,以增强抗体依赖性细胞毒性。FPA144预计将于2014年底启动I期临床研究,调查用于胃癌的治疗。(生物谷Bioon.com)

英文原文:Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways

SOUTH SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (Nasdaq:FPRX) and Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime’s proprietary target discovery platform.

Bristol-Myers Squibb will leverage Five Prime’s platform to advance its existing immuno-oncology programs by identifying the most viable drug targets for continued research and development. Drug candidates developed against these new and existing targets may be studied either as single agents or in combination with existing or potential Bristol-Myers Squibb immuno-oncology therapies.

“Immuno-oncology has the potential to be transformational in the treatment of cancer, and Bristol-Myers Squibb has an extensive clinical pipeline and discovery programs dedicated to maximizing this field of research,” said Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, Bristol-Myers Squibb. “Five Prime’s innovative technology platforms complement our immuno-oncology pipeline and will help expand our understanding of promising new therapeutic options for patients.”

“We are thrilled to enter this important collaboration with Bristol-Myers Squibb, an undisputed leader in the exciting field of immuno-oncology,” said Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime. “This strategic alliance is evidence that our protein discovery platform is ideally suited to identify novel immune checkpoint targets for the development of next generation immuno-oncology therapeutics.”

Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize products directed toward certain protein targets identified by Five Prime prior to and during the collaboration. Bristol-Myers Squibb will make an upfront payment of $20 million to Five Prime and provide up to $9.5 million in research funding over the course of the research term. Additionally, Bristol-Myers Squibb will make a payment of approximately $21 million to acquire 4.9% of Five Prime’s outstanding common stock purchased at approximately a 30% premium. Five Prime will be eligible to receive up to $300 million in future development, regulatory and sales based milestone payments per collaboration target and tiered mid-single-digit rising to low-double-digit royalty payments on net sales of each product commercialized by Bristol-Myers Squibb.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases. Five Prime has leveraged its comprehensive library of human extracellular proteins and its proprietary high-throughput screening technologies to produce new targets for protein therapeutics to be advanced by partners or in the company's internal pipeline. Five Prime currently has 2 therapeutics in clinical testing and a third anticipated to enter the clinic by the end of 2014. FP-1039 (GSK3052230) is a fibroblast growth factor (FGF) ligand trap being developed in collaboration with GlaxoSmithKline to treat multiple solid tumors. A global, multi-arm Phase 1b study of FP-1039 in combination with standard chemotherapy in FGFR1 gene-amplified squamous non-small cell lung cancer (NSCLC) and mesothelioma is underway. A second drug candidate is FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R) activation and is being developed to treat rheumatoid arthritis, is in a Phase 1 trial currently enrolling. FPA144 is a monoclonal antibody that blocks signaling through fibroblast growth factor receptor 2b (FGFR2b) and is glyco-engineered for enhanced antibody-dependent cytotoxicity. FPA144 is expected to begin a Phase 1 study in gastric cancer by the end of 2014.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库